Clinical significance of anaemia in chronic hepatitis c on the combined antiviral therapy with pegylated
https://doi.org/10.22625/2072-6732-2011-3-3-101-107
Abstract
In order to study the effect of combination antiviral therapy for hemoglobin and red blood cells in patients with chronic hepatitis C were estimated absolute numbers of red blood parameters. To determine the relation between the content of red blood cells and hemoglobin at different stages of antiviral therapy with the initial clinical and laboratory parameters (gender, age, body mass index, genotype, level
of viremia, ALT, fibrosis), as well as the results of combined antiviral therapy. Established that the decrease in hemoglobin levels were observed more frequently than the decline in the number of erythrocytes (63,6% and 21,1% respectively). In addition, anemia that occurred during treatment of HCV patients with pegylated interferon-α, directly correlated with the rate of sustained virological response. The study established prognostic criteria, indicating the possible development of anemia in the background of anti-viral therapy: the female sex, BMI <20 kg/m2, 1 genotype of HCV.
About the Authors
K. V. Zhdanov
Military Medical Academy named by S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
D. A. Gusev
Military Medical Academy named by S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
K. V. Kozlov
Military Medical Academy named by S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
A. V. Shekurov
Military Medical Academy named by S.M. Kirov, Saint-Petersburg
Russian Federation
Russian Federation
References
1. Лобзин, Ю.В. Вирусные гепатиты: клиника, диагностика, лечение / Ю.В. Лобзин [и др.]. – СПб.: ООО «Издательство Фолиант», 2003. – 192 с.
2. Fried, M.W. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection / M.W. Fried [et al.] //N. Engl. J. Med. – 2002. – V. 347. – Р. 975–982.
3. Manns, M.P. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial / M.P. Manns [et al.] //Lancet. – 2001. – V. 358. – P. 958–965.
4. Никитин, И.Г. Лечение хронического гепатита С: вчера, сегодня, завтра / И.Г. Никитин // Росс. журн. гастроэнтерол., гепатол., коло проктол. – 2002. – № 6. – С. 11–16.
5. Kowdley, K.V. Hematologic side effects of interferon and ribavirin therapy / K.V. Kowdley // J. Clin. Gastroenterol. – 2005. – V. 39, Suppl. – P. 3–8.
6. Mark, A. Interferons play a central role in the natural defense and therapeutic management of hepatitis C: a re view /A. Mark, R.N. Outzen // Internet J. Gastroenterol. – 2007. –V. 5 (2).
7. Ong, J.P. Managing the hemotologic side effects of antiviral therapy for chronic hepatitis C: anrmia, neutro penia, and thrombocytopenia / J.P. Ong, Z.M. Younossi // Cleveland Clin. J. Med. – 2004. – V.71, Suppl. 3. – P. 17–21.
8. Sulkowski, M.S. Management of the hematologic complications of hepatitis С therapy / M.S. Sulkowski // Clin. Liver. Dis. – 2005. – V. 9. – P. 601–616.
9. Pellicano, R. Autoimmune manifestation during interferon therapy in patients with chronic hepatitis C: the hepatologist’s view / R. Pellicano [et al.] // Minerva gastroenterol. dietol. – 2005. – V. 51. – P. 55–61.
10. Davis, G.L. Early virologic response to treatment with peg interferon alfa-2b plus ribavirin in patients with chronic hepatitis C / G.L. Davis [et al.] // Hepatology. – 2003. – V. 38. – P. 645–652.
11. Poynard, Т. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis С virus / Т. Poynard [et al.] // Lancet. – 1998. – V. 352. – P. 1426–1432.
12. McHutchison, J.G. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N. Engl. / J.G. McHutchison [et al.] // J. Med. – 1998. – V. 339. – P. 1485–1492.
13. Maddrey W.C. Safety of combination interferon alfa-2b/ribavirin ther¬apy in chronic hepatitis C-relapsed and treatment-naive patients / W.C. Maddrey [et al.]. – Semin. Liver Dis. – 1999. – № 19 (Suppl. 1). – Р. 67–75.
14. Martinб L.M. The impact of liver dis¬ease on healthrelated quality of life: a review of the literature / L.M. Martin, M.J. Sheridan, Z.M. Younossi // Curr. Gastroenterol. Rep. – 2002. – № 4. – Р. 79–83.
15. Spiegel, В.М. Impact of hepatitis С on health elated quality of life: a systematic review and quantitative assessment /В.М. Spiegel [et al.] // Hepatology. – 2005. – № 41. – Р. 790–800.
16. Жданов, К.В. Лейкопения и нейтропения у больных хроническим гепатитом С на фоне различных вариантов комбинированной противовирусной терапии / К.В. Жданов [и др.] // Журнал инфектологии. – 2011. – Т. 3, № 2. – С. 74–80.
17. Исаков, В.А. Рибавирин и его аналоги: будут ли они использоваться в новой комбинированной терапии? / В.А. Исаков // Программа научной конференции «Хронические вирусные гепатиты 2011: новые возможности диагностики и лечения» под эгидой европейской ассоциации по изучению печени. – СПб.: Elsevier, 2011. –C. 26–27.
Review
For citations:
Zhdanov K.V., Gusev D.A., Kozlov K.V., Shekurov A.V. Clinical significance of anaemia in chronic hepatitis c on the combined antiviral therapy with pegylated. Journal Infectology. 2011;3(3):101-107. (In Russ.) https://doi.org/10.22625/2072-6732-2011-3-3-101-107
Views:
1613
.png)
.png)
Email this article 